Clinical trials: Schizophrenia Spectrum Disorder
Schizophrenia
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders.
- Trial name
- DPTP (NCT02880995)
- Testing
- PET scan, clinical scale, 6 weeks of treatment with amisulpride
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia, Aging
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
The 2020 NIMH Strategic Plan for Research calls for investigations targeting neurobiology of mental illness across the lifespan.
- Conditions
- Schizophrenia, Aging, Disease Course, Biomarker
- Trial name
- NCT04951700
- Testing
- Other
- Where
- United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels
The main objective of the study is to analyse the role of a neurotrophic factor (BDNF) as a putative biological marker of the cognitive recovery in schizophrenia following a Cognitive Remediation Therapy (CRT).
- Trial name
- NCT02341131
- Testing
- Cognitive Remediation Therapy, Psychoeducation
- Where
- Spain
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia, Psychosis
Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release
Patients with schizophrenia show enhanced dopamine synthesis capacity and release, an effect that can be evoked in healthy subjects by repeated amphetamine administration.
- Conditions
- Schizophrenia, Psychosis, Sensitisation
- Trial name
- NCT03223844
- Testing
- Dextroamphetamine Sulfate
- Where
- Austria
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Psychosis, Schizophrenia
Remote State Representation in Early Psychosis
The purpose of this study is to examine state representation in individuals aged 18-30 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis.
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- Rem-STEP (NCT05538832)
- Testing
- BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm, BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Family Members
Family Peer Navigator for Early Psychosis for Black Families
Building upon formative research, this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component Family Peer Navigator model designed to increase access to and initial engagement…
- Trial name
- NCT05284721
- Testing
- Family Peer Navigator for Early Psychosis, Care Coordination
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington State University
Schizophrenia
The Effect of tDCS on Schizophrenia With Negative Symptoms
The investigators conducted a randomized controlled trial to reveal the effect of tDCS on negative symptoms in patients with schizophrenia and its underlying mechanism using the neuroimaging and electrophysiology.
- Trial name
- NCT03729791
- Testing
- tDCS
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
The purpose of this study is to compare the bioavailability of 2 extended release paliperidone pellet formulations under fasting and fed conditions with a 2 mg paliperidone oral solution under fasting conditions.
- Trial name
- NCT00796640
- Testing
- ER Paliperidone
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia
The purpose of this study is to assess how oxytocin delivered intranasally changes regional brain blood flow measured by positron emission tomography (PET) in conjunction with oxygen-15 labeled water in persons with…
- Trial name
- NCT01123317
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
- Trial name
- NCT01429740
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Auditory Verbal Hallucinations in Schizophrenia
Auditory verbal hallucinations (AVHs) are speech perceptions in the absence of a relevant external stimulation. Some accounts of AVHs claim that a deficit in inner speech monitoring would cause the verbal thoughts of the patient…
- Trial name
- HAV (NCT01886417)
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Schizophrenia
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
The primary purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of paliperidone ER formulations with slow, target, and fast in vitro release rates after administration of a single 12 mg dose.
- Trial name
- NCT00791193
- Testing
- Paliperidone ER
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
The Effect of an Individual Empowerment Program Provided to Relatives of Schizophrenia Patients
Psychoeducation provided to family members caring for individuals with schizophrenia. Has been found to positively impact caregivers' psychological well-being and the effective management of schizophrenia patients.However…
- Trial name
- NCT07173192
- Testing
- Individual empowerment program
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Istanbul Arel University
Psychotic Disorders
Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis
The purpose of this study is to investigate the structural, functional and chemical brain abnormalities in patients with first episode psychosis and assess the evolution of these abnormalities during the course of the disease.
- Trial name
- NCT01688765
- Testing
- Observational
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Healthy Subjects
Cognitive Biases Under Ketamine
Characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis. Our assumption is that low dose ketamine results in reasoning biases by impairing the way uncertainty is…
- Trial name
- KETABI (NCT02235012)
- Testing
- Ketamine
- Where
- France
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome
Background: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two…
- Trial name
- FaSchi22 (NCT02634671)
- Testing
- schizophrenia, the 22q11 deletion syndrome, control group
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Schizophrenia, Epilepsy
A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
The purpose of this study is to evaluate the effect of valproic acid (VPA) on the pharmacokinetics (blood levels) of a single oral dose of an extended-release formulation of paliperidone in healthy male volunteers.
- Trial name
- NCT01060228
- Testing
- paliperidone ER, divalproex sodium ER
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
Considering the complex pathological mechanism and the poor treatment outcomes of schizophrenia, early detection and intervention gradually become the key work for the foundational and clinical research in schizophrenia.
- Trial name
- NCT03965598
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.
- Conditions
- Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
- Trial name
- CNTRACS (NCT07900893)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers.
- Trial name
- NCT04187560
- Testing
- LB-102
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.